Qiagen (NYSE:QGEN) Q3 2025 Earnings Call November 05, 2025 09:30 AM ET Speaker3Ladies and gentlemen, thank you for standing by. I am Katie, your Global Meet call operator. Welcome, and thank you for joining QIAGEN's third quarter 2025 earnings conference call webcast. At this time, all participants are in a listen-only mode. Please be advised that this call is being recorded at QIAGEN's request and will be made available on their internet site. The prepared remarks will be followed by a question-and-answer ...

Q3 2025 results Delivering results above outlook November 4, 2025 Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and/or regulatory approvals, financial and ope ...

Qiagen (QGEN) reported $532.58 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 6.1%. EPS of $0.61 for the same period compares to $0.59 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $525.99 million, representing a surprise of +1.25%. The company delivered an EPS surprise of +5.17%, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Qiagen (QGEN) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +5.17%. A quarter ago, it was expected that this diagnostic products maker would post earnings of $0.6 per share when it actually produced earnings of $0.6, delivering no surprise.Over the last four quarters, the company ha ...

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets. QIAGEN reaffirmed its FY 2025 outlook for net sales growth of about 4-5% CER (about 5-6% CER core sales excluding divestments) and raised its adjusted diluted EPS target to about $2.38 CER (previously about $2.35 CER). QIAGEN also expects an adjusted ...

VENLO, Netherlands & SEATTLE--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research. The acquisition will significantly expand QIAGEN's Sample technologies portfolio into the fast-growing single-cell sequencing market with highly scalable chemistry designed to power research involving up to millions a ...

VENLO, Netherlands, & GERMANTOWN, Maryland--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 4,000th placement of its QIAcube Connect instrument, a significant milestone in driving automation adoption for sample processing across life science and diagnostic labs. This accomplishment is underscored by the nearly 13,000 cumulative placements of QIAcube platforms globally since launch, and evidence of widespread trust given more than 29,900 cumulative placements of QIAGEN ...

核心观点 - Qiagen预计在2025年第三季度营收增长但盈利同比下降 财报实际表现与预期的对比可能影响其短期股价 [1] - 公司当前盈利预测指标组合使其难以被确定为强劲的财报超预期候选标的 [12][17] 财务业绩预期 - 预计季度每股收益为0.58美元 同比下降1.7% [3] - 预计季度营收为5.2599亿美元 同比增长4.8% [3] - 过去30天内 季度每股收益共识预期被下调0.67%至当前水平 [4] 盈利预测模型分析 - Zacks盈利ESP模型通过比较最准确预期与共识预期来预测财报惊喜 [7][8] - 正的盈利ESP结合Zacks排名1-3级时 预测盈利超预期的能力显著 成功率近70% [9][10] - Qiagen的最准确预期低于共识预期 盈利ESP为-0.73% Zacks排名为第3级 此组合难以预测其将超越每股收益预期 [12] 历史盈利惊喜记录 - 上一季度Qiagen实际每股收益为0.60美元 与预期完全一致 未产生惊喜 [13] - 过去四个季度中 公司有两次超越每股收益共识预期 [14] 同业公司比较 - 同业公司Syndax Pharmaceuticals预计季度每股亏损0.74美元 亏损同比收窄24.5% [18] - 预计季度营收为4869万美元 同比增长289.5% [19] - 其共识每股收益预期在过去30天内被下调13.9% 但盈利ESP为+0.23% Zacks排名为第4级 同样难以预测其将超越预期 [19][20] - 过去四个季度中 Syndax有三次超越每股收益共识预期 [20]

文章核心观点 - 文章旨在比较凯杰和阿卡迪亚制药两只股票对价值投资者的吸引力 [1] - 凯杰目前被认为是更具优势的价值投资选择 [7] 公司比较：Zacks评级 - 凯杰的Zacks评级为第2级（买入），阿卡迪亚制药的Zacks评级为第3级（持有） [3] - 凯杰的盈利前景改善程度可能强于阿卡迪亚制药 [3] 估值指标：市盈率 - 凯杰的远期市盈率为20.42，阿卡迪亚制药的远期市盈率为40.72 [5] - 凯杰的市盈增长比为2.52，阿卡迪亚制药的市盈增长比为7.49 [5] 估值指标：市净率与价值等级 - 凯杰的市净率为3.03，阿卡迪亚制药的市净率为4.37 [6] - 基于多项估值指标，凯杰的价值等级为B，阿卡迪亚制药的价值等级为C [6]

年度回顾与预期对比 - 当前时间点约为全年进度的四分之三 [1] - 需要回顾年初至今的实际表现与初始预期的对比情况 [1] - 关注期间内出现的最大意外情况 包括正面和负面 [1]